Raltegravir
ApprovedTerminated 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Human Immunodeficiency Virus (HIV)
Conditions
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
Trial Timeline
Oct 1, 2011 → Oct 1, 2013
NCT ID
NCT01448486About Raltegravir
Raltegravir is a approved stage product being developed by Merck for Human Immunodeficiency Virus (HIV). The current trial status is terminated. This product is registered under clinical trial identifier NCT01448486. Target conditions include Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND).
What happened to similar drugs?
13 of 20 similar drugs in Human Immunodeficiency Virus (HIV) were approved
Approved (13) Terminated (3) Active (7)
Hype Score Breakdown
Clinical
20
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00377065 | Pre-clinical | Completed |
| NCT03732625 | Approved | UNKNOWN |
| NCT03667547 | Approved | Completed |
| NCT03374358 | Approved | Completed |
| NCT02097108 | Phase 2 | Completed |
| NCT01978743 | Pre-clinical | Completed |
| NCT01767701 | Phase 2 | Completed |
| NCT01453933 | Approved | UNKNOWN |
| NCT01620736 | Phase 2 | Withdrawn |
| NCT01453192 | Phase 3 | Completed |
| NCT01448486 | Approved | Terminated |
| NCT01327482 | Pre-clinical | Completed |
| NCT01325051 | Phase 1 | Completed |
| NCT01042652 | Pre-clinical | UNKNOWN |
| NCT01164605 | Pre-clinical | UNKNOWN |
| NCT01087840 | Approved | Completed |
| NCT01027182 | Phase 1 | Completed |
| NCT00939874 | Approved | Completed |
| NCT00807443 | Phase 2 | Completed |
| NCT00887653 | Phase 3 | Completed |
Competing Products
20 competing products in Human Immunodeficiency Virus (HIV)